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Abstract
Background: Epilepsy is a common neurological condition, in which drugs are the mainstay of
treatment and drugs trials are commonplace. Understanding why patients might or might not opt
to participate in epilepsy drug trials is therefore of some importance, particularly at a time of rapid
drug development and testing; and the findings may also have wider applicability. This study
examined the role of patient perceptions in the decision-making process about recruitment to an
RCT (the SANAD Trial) that compared different antiepileptic drug treatments for the management
of new-onset seizures and epilepsy.
Methods: In-depth interviews with 23 patients recruited from four study centres. All interviews
were tape-recorded and transcribed; the transcripts were analysed thematically using a qualitative
data analysis package.
Results: Of the nineteen informants who agreed to participate in SANAD, none agreed for purely
altruistic reasons. The four informants who declined all did so for very specific reasons of self-
interest. Informants' perceptions of the nature of the trial, of the drugs subject to trial, and of their
own involvement were all highly influential in their decision-making. Informants either perceived
the trial as potentially beneficial or unlikely to be harmful, and so agreed to participate; or as
potentially harmful or unlikely to be beneficial and so declined to participate.
Conclusion: Most patients applied 'weak altruism', while maintaining self-interest. An emphasis on
the safety and equivalence of treatments allowed some patients to be indifferent to the question of
involvement. There was evidence that some participants were subject to 'therapeutic
misconceptions'. The findings highlight the individual nature of trials but nonetheless raise some
generic issues in relation to their design and conduct.
Background
Within the framework of biomedicine, randomised con-
trolled trials (RCTs) are seen as providing the most valid
means of establishing the efficacy of treatment for condi-
tions of ill health but are inherently difficult to recruit to
'precisely because of the randomisation element that
makes them so statistically attractive' [1]. Low recruitment
impacts on both the progress and scientific quality of tri-
als [2,3], with many either failing to start or stopping due
to lack of participation, and those that continue being
subject to potential bias because of failure to recruit repre-
sentative samples of patients. This has stimulated concern
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and consequently, interest in the processes around
patients' decision-making concerning participation. Previ-
ous studies have explored both generalised attitudes
towards hypothetical RCTs among patients and the gen-
eral public [4-9] and the perceptions of real-life trial par-
ticipants about their experience of participation [10-13];
have involved both healthy and non-healthy trial partici-
pants and their proxies [14-17] and potentially eligible
patients [18-21]; have encompassed similar and highly
contrasting treatments [14-16,18-20,22] and have been
conducted across varying states of health emergency and
non-emergency [16,17,21,24]. These studies have high-
lighted both drivers and barriers to patient participation.
Large among suggested drivers for participation in clinical
trials is the notion of altruism [6-14,24]. Indeed,
Emmanuel and Patterson [25] go so far as to state that 'the
only legitimate justification' for randomisation is 'that the
patient chooses to be altruistic.' Certainly the idea that
patients should be involved in research is strongly
endorsed by non-patients and patients alike [5,8-11,14].
In the study by Searight & Miller [14], patients often
emphasised taking part in clinical trials as performing a
valuable service to the community of sufferers to which
they belonged. However, studies exploring motivations
for taking part in medical research, including trials, have
found that patients are also driven by reasons of self-inter-
est, seeing it as a means of ensuring treatment by a special-
ist or securing the best available therapies and medical
care [6-13,15,16,26]. Schutta and Burnett [18] note that in
their investigation, patients expressed surprise that people
would participate in clinical trials for altruistic reasons.
Both individual studies [6-9,14] and systematic reviews of
the literature [2,3,27] have so far drawn opposing conclu-
sions about the relative weight given to altruism and self-
interest.
Other factors highlighted as motivating patients to partic-
ipate in clinical trials include the trust they hold in their
doctor [22,23] and in the study [20]. Less positively,
patients may be influenced to take part because they hold
'therapeutic misconceptions' [28] about what involve-
ment will mean. Lidz et al [28] have argued that therapeu-
tic misconceptions arise from patients' failure to 'grasp
that the risks they face from participating in research pro-
tocols are inherently different from those involved in
receiving ordinary treatment' and when they inaccurately
attribute, 'a primacy of therapeutic intent and individual-
ized care typically seen in ordinary clinical settings to
research procedures.' These authors highlight a number of
studies in addition to their own suggesting that therapeu-
tic misconception on the part of trial participants is not
uncommon, with subjects underestimating risks [29],
over-estimating benefits [30] and conflating research and
ordinary treatment [29].
Potential barriers to participation in clinical trials have
been identified as: unwillingness to accept the possibility
of clinical uncertainty and equipoise [4,20,25]; unwilling-
ness to accept the idea of treatment allocation at random
[4-6,17,19,23], the possibility of being randomised to pla-
cebo rather than active treatment [13,21,23] and holding
clear preferences for a particular method of management
[26]; worry about receiving 'experimental' treatments [6]
or being used as 'guinea pigs' [8,24]; reluctance to change
treatment [7]; the belief that trial participants might be
denied access to new treatments or that the trial did not
offer the best available treatment [21,23] and the view
that any benefits of taking part would not outweigh the
risks [15,21,24,26]. Distrust of the medical profession
and lack of knowledge of what is required of trial partici-
pants have also been highlighted as potential barriers
[22]; as has inconvenience and discomfort [2,12] and fear
of side-effects [7,26]. Fallowfield at al [5] identified three
distinct groups of patients with regard to clinical trial par-
ticipation: those for whom the concept of randomisation
was acceptable and who would therefore agree to partici-
pate in clinical trials; those who had concerns about the
concept, but were nonetheless open to considering partic-
ipation; and those who were firmly against randomisation
and participation in trials.
While patient-related factors are clearly crucial to the issue
of trial recruitment, investigators have also identified
other clinician- and trial-related factors that may influence
recruitment rates. Systematic reviews have [2,3,22] listed
among clinician-related factors logistic difficulties such as
lack of time and resources, and difficulties with ethical
requirements; and personal difficulties such as discomfort
with randomisation and preference for a particular treat-
ment, concerns about the effect on the doctor-patient rela-
tionship, and difficulty with informed consent
procedures. Roberts [31] and Donovan et al [32] have
both explored qualitatively how different clinicians' pres-
entation of the same clinical trial can vary substantially,
with important implications for recruitment. Trial factors
include poorly designed or complex protocols, presence
of a no-treatment arm or too large a difference between
active treatments, and concerns about treatment toxicity
[22].
Based on their review of the existing literature, Ross et al
[3] conclude that further research is needed to understand
more clearly reasons why patients do or do not take part
in clinical trials; and that such work can be nested within
ongoing trials. We have examined the issue of participa-
tion in clinical trials in the context of a common chronic
condition, epilepsy, and a non-controversial intervention,Page 2 of 13
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compared [33]. Epilepsy is the commonest serious brain
disorder [34]; and is characterised by recurrent unpro-
voked seizures which in most patients can be successfully
treated and controlled [35]. Though there is an expanding
surgical programme for epilepsy worldwide, drugs remain
the mainstay of treatment. Recent advances in under-
standing of the basic mechanisms for seizures have led to
a period of rapid drug development and testing, so that
drug trials are now commonplace. Understanding why
patients might or might not opt to participate in epilepsy
drug trials is therefore of some importance within the field
itself, but may also offer some more general insights. Sur-
prisingly, given the level of activity in the field, we are una-
ware of any of studies exploring this issue in relation to
epilepsy trials.
Studies exploring patients' reasons for participation or
non-participation have so far focussed on trials that have
involved testing new or markedly different treatments
[20,32] and trials conducted in situations of clinical emer-
gency [17,23] or of treatment for life-threatening condi-
tions [5,10,18], which have therefore proved difficult to
recruit to. The situation around which our study was
framed was in marked contrast to these, in that the UK
SANAD study was a trial of six currently available drug
treatments for a chronic and, in the main, clinically
benign condition, epilepsy. (SANAD is the acronym for
'Standard And New Antiepileptic Drugs'; SANAD was
funded by the UK NHS Health Technology Assessment
Programme; ISRCTN number 38354748.)Patients poten-
tially eligible for SANAD were those with a newly con-
firmed diagnosis of epilepsy, for whom treatment with a
single AED (monotherapy treatment) was indicated.
SANAD proved a highly successful trial, recruiting over
2,000 such individuals, from 90 centres across the UK. It
therefore presented an interesting and timely opportunity
to explore, using a nested study design, the role of patient
perceptions and understandings in the decision-making
process about recruitment to epilepsy drug trials; and their
actual rather than hypothetical reasons for either agreeing
or declining to participate.
Unusually in the context of clinical trials, all the drugs
included in SANAD were already available to patients
within the NHS, though two were not licensed for use as
monotherapy at the time of trial recruitment. The two
standard drugs, Sodium Valproate and Carbamazepine,
are currently considered to be first-line treatments for epi-
lepsy, with the other four recently licenced drugs (Lamot-
rigine, Oxcarbazepine, Gapapentin, Topiramate) being
prescribed, in the main, only when they have failed. In
spite of this, there has been a steady rise in the prescribing
of the newer AEDs from 0.1% of total AED prescriptions
in 1991 to 20% in 2002. Because of the much higher costs
of these newer drugs relative to the standard ones, a recent
NICE appraisal estimated that they now account for 69%
of the total costs of AEDs to the NHS [36]. SANAD was
therefore funded as a Phase IV trial to provide information
on the clinical utility of these newer AEDs. The aims of our
nested 'participation' study were:
1. to examine adult patients' and parents reasons for
agreeing or declining to take part in the SANAD trial;
2. to explore their perceptions of SANAD and understand-
ing of the nature of this particular clinical trial, and how
these perceptions and understandings contributed to their
enrolment decisions;
3. to consider whether there were lessons to be learned
about how the recruitment process in future trials in epi-
lepsy might be improved.
Methods
As outlined above, SANAD was a multi-centre, pragmatic,
unblinded, parallel-group RCT, which compared mono-
therapy with clinicians' first-choice standard AED versus
appropriate comparators from among the newer AEDs
[33]. By the end of the 6-year recruitment phase in August
2004, almost two and a half thousand individuals aged
over five years (92% of all eligible individuals) had been
randomised to SANAD. The majority of those randomised
were adults (81%, see Table 1); and a somewhat higher
proportion of decliners were parents of children aged
under 16 years. In all, 6% of eligible adults and 11% of
parents of eligible children declined to take part.
Recruitment to SANAD took place within a consultation
at which the clinician first had to confirm a diagnosis of
epilepsy. Typically, recruitment consultations began with
a detailed history taking and examination, at the end of
which the clinician reached a conclusion about whether
or not the patient was experiencing seizures. If a diagnosis
Table 1: Recruitment to SANAD Trial
Adults Children All
Eligible 2119 (81%) 508 (19%) 2627 (100%)
Randomised 1987 (82%) 450 (18%) 2437 (100%)
Declined randomisation 132 (69%) 58 (31%) 190 (100%)Page 3 of 13
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implications, both in relation to broader 'quality of life'
issues and to treatment options specifically, including the
likelihood of a seizure recurrence if treatment was with-
held. For the patient, confronting the decision whether to
begin treatment and uncertainties about treatment out-
comes was thus a major element of the consultation. Only
when patients accepted the need for treatment were they
approached to take part in SANAD. They were given oral
and written descriptions of the trial, which explained its
rationale, the process of randomisation, possible risks and
benefits of participation, the length of the trial (six years),
and detailed information about the trial drugs and their
potential side effects. The trial information sheet high-
lighted that, drugs used to treat seizures were 'generally
safe' and that the study 'may benefit you personally and it
will also benefit other people who have seizures and epi-
lepsy.' Most patients made their decision about participa-
tion in SANAD on the same day as they were approached.
In order to recruit to the present 'participation' study, one
of the authors (KC), who was not otherwise involved in
the SANAD trial, attended 37 clinics (approximately 48
clinic hours) over a 13-month period across four hospi-
tals. The decision to limit recruitment to only four centres
(two adult and two paediatric neurology clinics at three
hospitals (A,B,C) in North West England and one in
North Wales (D)) was made for practical and logistic rea-
sons, all being easily accessible to the researchers. When
contact was made at clinic with eligible patients, KC gave
them printed information about the 'participation' study
and asked if they would be willing to be interviewed for it,
at a time and venue suitable for them.
The number of new patients (i.e. potentially eligible for
the SANAD trial and, in turn, for the participation study)
was approximately 8 per clinic. Therefore, the researchers
potentially had access to a pool of approximately 315
potential participants. We aimed to recruit up to 20 adults
and up to 20 parents who were making the decision about
recruitment to SANAD on behalf of their child, at the
point of randomisation; to include both consenters and
decliners in each group; and to interview them within a
month of the recruitment consultation. In the event, our
recruitment strategy proved less successful than we hoped,
although just five patients refused to take part in the 'par-
ticipation' study. Considerably fewer patients were
approached (a total of 43) for a number of reasons. First,
the pool of potential patients at each clinic attended was
considerably less than expected because patients proved
to be ineligible for SANAD (approximately 68% of those
not approached). For example, some were discharged
without a positive diagnosis and referred for further tests
or follow up. Second, some eligible patients failed to
attend the clinic appointment (approximately 24%).
Third, the logistics of clinic organisation meant some were
not flagged as eligible to KC (approximately 8%).
Furthermore, a high initial consent rate to the 'participa-
tion' study (88%, 38 of 43 eligible individuals who con-
sented to SANAD) fell to 51% (23/43) because 15 patients
agreeing to be interviewed when initially approached
either could not be re-contacted for an interview appoint-
ment, cancelled or failed to keep one that had been
agreed, or subsequently proved to be ineligible for
SANAD (Table 2). Of the 15, one had declined participa-
tion in SANAD, one withdrew after consenting initially
and the remaining 13 had consented. This report is there-
fore based on 23 individuals interviewed, of whom 15
(65%) were adult informants and eight were parents
(Table 3). Four patients (17%), all adults, had declined to
participate in SANAD and one, also an adult, had agreed
initially and then withdrawn. Of the 2,437 individuals
consenting to randomisation to SANAD, only 47 (2%)
subsequently withdrew consent. None of the parents we
interviewed had declined to allow their child to be entered
into SANAD, though one had decided not to take part ini-
tially and was then persuaded by her discussion with the
clinician to reverse her decision.
Face-to-face, topic-guided interviews were conducted by
KC in informants' homes on average 15 days after the
invitation to participate in SANAD (range of 3 to 32 days);
although in one unusual case, 73 days had elapsed.
Informants were first asked to recall the content of the
consultation where they had been asked to participate in
SANAD, then to describe their feelings, perceptions and
understandings about their diagnosis and treatment, and
the invitation to participate in SANAD, including the
information provided. Informants were asked about the
Table 2: Reasons for informants recruited but not interviewed
Number of informants recruited but not interviewed Reason
2 Interviewer unable to re-contact to make appointment
3 Patient cancelled appointment
4 Patient did not attend interview appointment
6 Patient proved ineligible for SANAD
15 TOTALPage 4 of 13
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consider the utility of the information received and what
they understood about the purpose of SANAD, the issue
of clinical uncertainty and the concept of random alloca-
tion.
All interviews were tape-recorded, with consent; and tran-
scribed verbatim. The data were analysed using a compu-
terised qualitative data analysis package (Atlas.ti). KC
generated codes through open coding and categorised
these thematically; relationships between themes were
then identified through constant comparison of the tran-
scripts, codes and categories [37]. AJ reviewed the codes
and their application and suggested alternative interpreta-
tions until consensus was reached about the interpreta-
tion that best fitted the data. Although we draw attention
here to themes that were more strongly associated with
particular groups (e.g. parents or decliners), many themes
were cross-cutting.
All quotes in the text have been anonymised: AA denotes
an adult patient who agreed to randomisation; PA
denotes a parent who agreed to randomisation; AD refers
to an adult patient who declined randomisation and PD a
parent who declined on behalf of their child.
Results
The context of recruitment
As described above, patients were recruited to SANAD
during a clinic consultation at which they were first con-
firmed as having epilepsy. Not surprisingly, even among
those who had realised they were experiencing seizures of
some kind and had suspected this to be the case, confir-
mation of their condition was generally unwelcome and
for some, something of a shock. An adult patient who, in
light of the family history (a close relative with epilepsy),
already suspected his symptoms were epilepsy noted that,
'in the back of my mind, I thought they [the symptoms]
are very similar, but I really didn't want to have the same'
(AA7). Another adult who also believed epilepsy was a
hereditary condition described receiving the diagnosis as
'traumatic' because:
'There is no history or trace of history of epilepsy any-
where at all in the family, not just in living memory, but
we have spoken about relatives and so on and there has
Table 3: Characteristics of informants
Informants (n = 23) Female/male Adult/parent of child Decision Hospital
1 Female Parent Consented A
2 Female Parent Consented C
3 Female Parent Consented C
4 Female Parent Consented C
6 Male Adult Consented B
7 Female Adult Consented D
8 Male Adult Consented B
9 Female Adult Consented B
10 Male Adult Consented B
11 Female Adult Consented B
21 Female Parent Consented A
22 Male Parent Consented A
23 Female Parent Consented A
13 Male Adult Consented D
15 Male Adult Consented B
16 Male Adult Consented B
17 Female Adult Consented B
19 Female Parent Consented A
14 Male Adult Withdrew D
18 Female Adult Declined B
5 Male Adult Declined B
12 Male Adult Declined B
20 Male Adult Declined B
TOTAL – n (%) Female – 12 (52%)
Male – 11 (48%)
Adults – 15 (65%)
Parents – 8 (35%)
Consented – 18 (78%)
Declined – 4 (18%)
Withdrew – 1 (4%)
A – 5 (22%)
B – 12 (52%)
C – 3 (13%)
D – 3 (13%)Page 5 of 13
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you're the first one to suffer from this problem, and to
have to come to terms with that.' (AA9)
Some informants expressed reluctance to accept the diag-
nosis; though for others it came as a relief to be able
finally to put a label to the symptoms they or their child
had been experiencing. However, the element of unex-
pectedness to the diagnosis meant patients and parents
were often unprepared for deciding whether to begin what
might prove to be long term drug treatment. It was in this
context that their reasons for agreeing or declining to take
part in SANAD were made.
Reasons for agreeing or declining to participate in SANAD
Reasons for participating in the SANAD trial can broadly
be seen as falling into one of three categories, which we
have defined as a sense of altruism or duty, personal
desire and self-interest, and a degree of neutrality or indif-
ference (Figure 1). These categories and the ways in which
they overlapped in patients' deliberations, are considered
below.
Duty as a driver for participation
In keeping with previous studies, all but five participants
in SANAD offered altruistic reasons and a sense of moral
duty for agreeing to participate, including: the wish to
help people with epilepsy; the wish to do their 'bit' and
'give something back' or help the researchers; the percep-
tion that they had a duty to participate; and the view that
the trial was a 'good idea' or necessary and would contrib-
ute to scientific knowledge. However, none of the inform-
ants in this study agreed to participate for purely altruistic
reasons: all who gave reasons that fell under what can be
broadly described as 'the wish to act for the greater good'
also gave reasons that represented self-interest and per-
sonal 'desire'. Three parent informants clearly articulated
their ideas relating to altruism – that trials have to be con-
ducted, and there is a duty to take part in them:
'Because it's got to be proved what, whether or not [...]
if people hadn't done this with Epilim and that, then
we wouldn't know if people were going to be able to
take it or not, it's got to be done.' (PA2)
'I mean it's not advancing medical research if there is
people not prepared to go in for the trial, and I think
to further, to help medical science, [...] I did it.' (PA19)
'When you think about it every drug they bring out has
to be tested in some way or other, hasn't it. So if
nobody got tested then we would all be in a right state,
wouldn't it. You can only take testing so far in a labo-
ratory can't you?' (PA22)
Yet, these parents also made separate comments indicat-
ing that they were also acting in what they saw as their
child's best interests and in the hope that she/he would
benefit directly.
Desire as a driver for participation
All 19 informants who agreed to participate in SANAD,
whether or not they proffered altruistic reasons, expressed
reasons of self-interest for doing so, including personal
preferences and desires about treatment. Some patients
actively wanted treatment, rather than no treatment, in
order to 'get it sorted out straight away' (AA10) and 'stop
this happening' (AA11); and others assumed that partici-
pation would lead to better treatment. Three informants,
all of whom actively wanted treatment, only gave reasons
related to self-interest. Several informants perceived tak-
ing part in SANAD as having immediate potential benefit
for them or their child. Others reasoned that as part of the
broader community of people with epilepsy, taking part
in SANAD might be of benefit to them in the longer term.
The perception of personal benefit, however indirect, was
apparent in many informants' responses, even when they
also gave altruistic reasons for participating:
KC: 'So why did you decide to take part?'
Informant: 'To help me.'
KC: 'To help you?'
Informant: 'To help me yeah. (...) if it helps other peo-
ple while they are sorting me out, then well and good.'
(AA17)
'Yeah, well, I thought if it helps other people it could
help me. 'Cause if I'm helping in it, they might find
something else that's linked to it in some way that they
didn't know before and then they can go, oh well, yeah
that bit matches that, so we can do something about
that. So they might be able to work something else
out. So that's the idea I've got.' (AA8)
However, perceptions of benefit appeared sometimes to
rest on a 'therapeutic misconception' [28]. First, some
informants appeared to be attributing 'primacy of thera-
peutic intent' [28] in as much as they believed that despite
the process of randomisation treatment would nonethe-
less be individualised. Second, some informants appeared
to over-estimate the potential benefits of taking part in
SANAD, seeing it as the means of securing the 'best' treat-
ment for them or their child:
' [Consultant] said he put all the information he had
about me, he would put it all in the computer, andPage 6 of 13
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thought was the best drug for me.' (AA17)
'I'm not a stupid person, I already thought I was saying
no, but then like I say, when [consultant] explained to
me that they were quite safe. I just thought, well, am I
denying my child the best treatment – and I thought it
is not right for me to be doing this.' (PA19)
Indifference to participation
A number of informants – mainly adult patients –
appeared to agree to participate less because they could
identify positive benefits than because they could not
identify any active harms. Taken together, their comments
conveyed a sense of neutrality, even indifference, about
participation, although the origins of this indifference
seemed to vary. For some patients, it appeared predicated
on the fact that they had certain expectations for their
treatment and once those expectations were fulfilled, they
were indifferent to participating in SANAD:
'I knew he was going to get medication anyway, so as
long as he's getting medication that's fine. If other peo-
ple are, you know, using that to see what to do, then
that's fine.' (PA4)
Other patients made comments suggesting their indiffer-
ence was tempered by a weak sense of duty:
' [Consultant] mentioned the fact that this study was
going on and had been going on for some time, and
was I interested in joining in. I said why not, it all had
to be done and I was quite happy to go along with [it].'
(AA16)
'So I thought if I can do my bit, well why not? It's no
skin off my nose is it?' (AA8)
Furthermore, a number of patients explicitly referred to
aspects of the trial design which may have allowed them
to act with apparent indifference. For example, a parent
(PA2) thought her child 'might as well be involved' but
then said that, had the drugs been experimental, she
would have 'been a bit more dubious' about consenting.
Finally, one patient's apparent indifference clearly
reflected an expression of trust in his doctor:
KC: 'So was it a concern then, that in fact it wasn't the
doctor picking the drug, that it was being picked ran-
domly by the computer?'
Reasons for agreeing or declining to participate SANADFigure 1
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computer is only there, just picking numbers and
whatever my number is it is, and whoever pro-
grammed it is going to be a doctor, so he is going to
know what he is doing – so you have just got to put
your trust in the doctor who has done the programme
to allocate you to whatever tablets. It doesn't really
bother me that much, to be honest.' (AA8)
In contrast, other informants emphasised how they were
not simply 'going along with' it. Indeed, some – mainly
parents – agreed to participate in the trial only on condi-
tion that certain beneficial criteria pertaining to the trial
were fulfilled – in particular that participation would not
cause any harm:
'I wasn't going to be pressurised into anything. I am
not the type of person that would go along with some-
thing I wouldn't do that, I asked a lot of questions
before I made my decision and I thought it was the
right thing to do.' (PA19)
'As long as it wasn't putting him [child] in danger then
yes, fine.' (PA4)
Desire as a barrier to participation
Informants who declined to participate in SANAD
expressed specific desires as to how they wished to pro-
ceed following their diagnosis, based on explicit self-inter-
ested reasons. These desires acted as a barrier to their
participation in SANAD. For example, one informant
(AD18) was reluctant to risk randomisation to drug that
could interact with the contraceptive pill or, indeed, to
begin any treatment at all until she had received counsel-
ling:
'Some of the drugs on the trial [nurse specialist] said
didn't interact well with contraception – you know,
the oral pill – and that was my biggest concern. I
wanted to make sure I was on a tablet that didn't affect
it. The computer randomly chooses the drug and I
thought, I don't want to get a drug that isn't going to
work for me.' (AD18)
Another (AD5) primarily wanted 'to get on with everyday
life':
'As long as I can, this medication doesn't, just taking
medication doesn't interfere with, I can still go out,
can still have a few drinks, I said fine, I wasn't really
too interested in the medical trial, as long as I'm stay-
ing fairly attack-free.' (AD5)
He was concerned that the trial 'might be a bit of a disrup-
tion' but also rejected taking part in clinical trials as fright-
ening, just not 'my thing' and a 'last resort' only in the
event of being unhappy with his treatment. The third
(AD12) based his decision to decline on his desire to
avoid the treatment a brother, also treated for epilepsy,
had been prescribed. The brother's experience of that
treatment had been negative, and AD12 realised he might
be randomised to that treatment if participating in
SANAD:
'The fact was I wasn't coming into this blind, my
brother has been through all this, so I had a reference
point, otherwise I would have gone in there thinking I
had no idea. .... When we got to the bit about the clin-
ical trial, once I had established that I might land,
because it is random, on the one that my brother def-
initely had problems with, I said to be honest that is
putting me off and I said I would rather do it on a one
to one basis.' (AD12)
His desire not to participate outweighed the fact that, in
principle, he supported the need for clinical trials and
expressed willingness to act as 'a guinea pig'. The fourth
(AD20) wished to take a proven clinical route, rather
than, as he perceived it, accepting the 'unknown' route of
participating in a clinical trial. Accordingly, there were ele-
ments of the trial he 'wasn't willing to go along with' par-
ticularly the risk of drug side effects:
'So I thought as I weighed them up, there were other
sorts of side effects that could or could not arrive that
I wasn't willing to go along with, so that's why I was
turned off at that stage.' (AD20)
This individual was also reluctant to accept the diagnosis
of epilepsy; and so to accept the need for treatment, either
within the framework, or independent of a clinical trial.
One adult (AD14) expressed the desire not to be involved
in SANAD based on his views about its purpose and his
belief that 'whether I get better faster or not' was not a con-
sideration:
'The big question mark is if there are two existing drugs
which adequately treat seizures, then what is the rea-
son for trying another four, except for perhaps reasons
of economy or perhaps reasons of politics were other
pharmaceutical companies are being let in to the
scheme of things for purely economic or political rea-
sons nothing to do with whether I get better faster or
not. And you will just have to excuse me for being
slightly cynical about these things. And I don't want to
be involved in that.' (AW14)
So, despite initially agreeing to participate, he almost
immediately withdrew agreement. Again, his desire not toPage 8 of 13
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view that trials were 'a positive activity to be involved in'.
Hence, like those who agreed to participate, these five also
acted in what they saw as their own best interests (see Fig-
ure 1).
Aspects of SANAD that influenced patients' decision-
making
Perception of treatments as tried and tested
As previously described, SANAD was a Phase IV pragmatic
trial involving drugs already available through the NHS
and about which a considerable amount of information
about efficacy and side effects was already available from
earlier phase trials. Unsurprisingly, this aspect of the trial
was very important to informants who were concerned
about their safety; and several expressed willingness to
participate based on their understanding that the drugs
were not really new and 'experimental', but already effec-
tively 'tried and tested' and therefore safe:
'Well it was fine, because it wasn't like it was, they just
plucked, like somebody had just discovered some-
thing and said well, you're trying that!' (PA2)
Indeed, they were able to be reassured on this point by the
wording in the patient information leaflet, where it was
stated that clinical trials had shown them to be safe, but
that there was no good information as to whether they
were 'more effective or safer' than the older drugs.
One parent, who had initially intended to decline partici-
pation because she did not want her child to have
'untested medicines', was persuaded by reassurances from
the doctor of the extent of evidence of their safety:
'He [consultant] said I would like you to participate,
and that's when I started asking questions – Are they
safe? Have they been tested? How much do you know
about them? And things like this and he said of course
they are safe, they wouldn't have been passed, we
know quite a lot about them, but what we don't know
is whether they work any better than the old type of
drugs. No, I'm not worried, I just think at the end of
the day, doctors wouldn't prescribe something that is
going to do my child any harm. I do have a lot of faith
in the health system.' (PA19)
Perception of treatments as equivalent
Among informants in this study, willingness to participate
in SANAD appeared to rest less on an appreciation of clin-
ical equipoise (i.e. that there is no consensus about the
comparative merits of the treatments being tested [38])
than on a perception of treatment equivalence (i.e. that
the drugs under scrutiny were all broadly similar). A
number of informants who consented referred – without
being prompted by the researcher – to the similarity of the
treatments involved:
'He said you have got five or six different tablets and
they all do basically the same job, but you have got dif-
ferent side effects and then he showed me the booklet,
I read it though and he said would you like to go on
part of the study? And I said yes, straight away. I
thought if they all do the same job, it's no bother to
me, side effects or no side effects.' (AA10)
Based on their descriptions of the encounter with the
recruiting clinician, these references to the equivalence of
treatments seemed to have originated from the clinician's
perhaps overly optimistic emphasis on the similarity of
the various treatments, rather than the possibility of dif-
ference.
In contrast, for those declining to take part, the emphasis
was not so much treatment equivalence as the uncertain-
ties around SANAD. All four informants who declined
from the outset and the one who initially consented and
subsequently withdrew all expressed discomfort about
what they perceived to be uncertainty about the process
and outcome of participation:
'It is an unknown quantity, I don't want to be involved
in something like that where the outcome is uncertain
– the outcome must be uncertain, because otherwise
why bother to do a study.' (AW14)
'It is difficult to make choices, you know what I mean,
I have no idea of medical matters as I said so I really,
rather than go down a path which was to my mind
somewhat unknown I preferred the path that had
already been proven.' (AD20)
Three of these individuals explicitly rejected randomisa-
tion and the idea that 'I might just land on any one'
(AD12) of the drugs involved.
Perception of participation as voluntary and reversible
The perception that participation in the trial was volun-
tary and reversible was another important influence on
informants' decision-making. Many informants empha-
sised the voluntariness of their engagement with SANAD,
and that they were not put under pressure to do so.
Though several informants declared themselves unboth-
ered and even actively in favour of randomisation, many
raised the reversibility of their initial decision as impor-
tant, both of the decision to participate at all and of
aspects of the trial such as the choice of drug. This element
of the trial design appeared especially important to the
parents of children who entered, 'because nobody wants
to put their kids in danger, no matter what for' (PA4).Page 9 of 13
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stop or adjust the drug treatment easily, that there was 'a
get out clause' in the words of one parent (PA19), despite
taking part in a trial:
'He [consultant] put me under no pressure whatsoever.
He said if at any time you want to stop it then you can
do, he said there is no pressure at all, you can stop it at
any time and go back to the old drug.' (PA22)
'I was concerned about the tablets having [side-effects]
and [nurse specialist] was saying that it's only rare and
should it happen, the moment it happens, we will
change you off that one and put you on a different
one.' (AA15)
In summary, then, informants' perceptions of the nature
of the SANAD trial were highly influential in their deci-
sions to agree or decline to participate. Broadly speaking,
informants either perceived the trial as potentially benefi-
cial (or at least unlikely to be harmful) and focussed on
participation as easily reversible – and so agreed to partic-
ipate; or as potentially harmful (or at best unlikely to be
beneficial) and focussed on the uncertainties involved –
and so declined to participate.
Discussion
In agreeing to participate in a clinical trial, patients should
first accept clinical definitions of disease and the need for
treatment, then be willing to entertain the possibility of
clinical equipoise about which treatment to offer and the
need for evidence to resolve it, the role of clinical trials in
providing such evidence, and the need for randomisation
as an essential element in trial design. All these elements
were detectable across the range of comments made by
informants who agreed to participate in SANAD. These
individuals all accepted the clinician's definition of their
symptoms as meaning they had epilepsy, and his/her rec-
ommendation that they therefore start treatment; under-
stood that a number of treatment options were available;
and appeared to accept that these were treatments about
which some uncertainty persisted even though much was
already known. Some, though not all, were explicit in
their acceptance of randomisation; and most believed that
they could reverse their decision easily and without impli-
cations for their condition or continuing treatment. Some
also explicitly and others implicitly expressed their trust in
the clinician, another element previously shown to be crit-
ical to participant agreement [23,39,40]. Importantly, sev-
eral felt able to be reassured about the safety of the
treatments under test and none expressly rejected any
aspects of trial design. In contrast, the few informants who
had declined to participate in SANAD accepted some but
not all of these elements. One decliner was reluctant to
accept the diagnosis of epilepsy; another accepted the
diagnosis but was unconvinced about the need for treat-
ment; two rejected the principle of randomisation, prefer-
ring treatment to be given 'on a one-to-one basis'. Like the
trial non-participants in the study by Featherstone and
colleagues [19] these individuals had clear and specific
beliefs and treatment preferences, the latter potentially
unattainable due to the process of randomisation; and all
perceived that participation was potentially harmful.
The common element upon which both participants' and
decliners' decisions hinged was thus their perception of
whether participation would be beneficial or harmful. In
Snowdon's study [41] of parents' decision-making about
a neonatal treatment trial, those who accepted participa-
tion saw the research as either desirable, acceptable or not
an issue, and the risks as worth taking; whereas for parents
who declined participation, there was a high level of dis-
comfort over the notion of experimentation and the risks
were seen as unacceptable and clearly not in their child's
best interests. Snowdon comments that, 'decliners placed
it [the study] outside of the therapeutic setting in the unset-
tling realms of experimentation' and, not perceiving any
particular benefits to participation, gave more promi-
nence to the possible risks. A similar process seemed to be
in train in SANAD despite the very different clinical setting
– those agreeing to take part generally saw the risks of
doing so as acceptable or not an issue, in this case because
of the 'tried and tested' nature of the treatments and their
broad similarity. In contrast, the five decliners saw taking
part as 'an unknown quantity' and, like the decliners in
Snowdon's study, defined the risks of being randomised
to an unsuitable drug as unacceptably high and not in
their best interests.
Two important reasons given for participation in SANAD
were sympathy for the aims of the research and a sense of
duty to take part. Informants spoke of the trial as a good
idea, and as contributing to scientific knowledge; and
themselves as wanting to be, in Harris's [42] words, 'pub-
lic-spirited'. In this sense, our study mirrored findings of
other earlier studies and supported previous claims that
altruism is a key driver for participation. Their comments
suggested that most would, if presented with it, acquiesce
to Harris's claim that we all 'have an obligation in justice
to contribute to the social practice which produces' medi-
cal advances. However, as described above, none of our
informants cited only public-spirited reasons for partici-
pation – all also gave reasons related to self-interest. The
term 'weak altruism' [43], though originally proposed as
descriptive of a situation where patients consent to take
enter a trial only because they perceive 'no positive net dif-
ference' between treatments and so do not expect to lose
out, may usefully be extended to the describe the situation
in SANAD where informants were happy to help others,
but only where they could also help themselves. However,Page 10 of 13
(page number not for citation purposes)
Trials 2006, 7:32 http://www.trialsjournal.com/content/7/1/32the nature of the SANAD trial also allowed informants to
operate within the original definition of 'weak altruism',
of being altruistic only 'in the weak sense that they are
actively consenting to randomisation instead of passively
accepting a default treatment' [43]. As previously
described, SANAD was a trial of treatments already avail-
able outside the research context, the advisability of start-
ing treatment had been discussed, and informants were
often reassured by their discussions with the recruiting
doctors that there were no net differences between treat-
ments. These conditions may well have enabled them to
be weakly altruistic, without any significant infringement
to self-interest.
Corrigan [44] has noted a high level of ambivalence
among the general public with regard to new or experi-
mental drugs. The finding that informants who agreed to
participate in SANAD were often clearly influenced by
their understanding that even the 'new' drugs were not
really new as they had been tested and were safe (and were
in all likelihood 'better' than the older drugs) is therefore
of some importance, in as much as it contributed to their
being able to frame it as a low-risk enterprise. Previous
studies [20,32] have highlighted that the issue of clinical
equipoise plays an important role in patients' willingness
to participate in clinical trials, those unwilling to accept
the concept of equipoise being less likely to participate. In
our study, however, it is possible that in some cases clini-
cians' explanations of the trial led to a situation where
equipoise played a minor role in informants' decision-
making compared to their perceptions of the equivalence
of the treatments. Since we were unable to tape-record
recruitment consultations, we are unable to clarify to what
extent the emphasis on equivalence rather than equipoise
reflected the clinicians' emphasis or informants' interpre-
tations. However, this subtle difference in the way inform-
ants came to perceive the trial question seems to have
been instrumental in their willingness to take part, sug-
gesting further exploration of how these related but dis-
tinct aspects of treatment can be conveyed to patients is
warranted. Both the focus on equivalence and the misin-
terpretation of the process of randomisation as nonethe-
less involving individualised care suggest some
informants made their decisions about participation in
SANAD based on a 'therapeutic misconception' about the
risks involved. This, in turn, raises a question as to
whether clinicians may have been sometimes overly opti-
mistic or overly simplistic in their presentation of infor-
mation about the various treatments or insufficiently
clarified the impact of features of clinical trial design, and
so exercised what has been described as 'unwitting coer-
cion' [45] on potential participants. Our findings concur
with those of Jenkins et al [46], that there may be areas of
discussion that can be improved. The importance of iden-
tifying and addressing reasons for such misconceptions in
future trials is self-evident.
The centrality of trust in relation to healthcare, and the
increasing tendency towards mistrust have recently been
highlighted by a number of authors [47,48]. In our study,
as in others recently reported [39,40,44], trust in the doc-
tor seemed to be an important element in the process of
recruitment. Though it was an issue only infrequently
raised explicitly, informants often made statements about
their decision which were reflective of trust: for these
patients, clinicians' reassurances about the safety and
equivalence of treatments may have served as a signal to
acceptance of randomisation. Our finding parallels that of
Corrigan [44] who concludes that in the context of a clin-
ical trial, where patients are seeking advice and reassur-
ance about treatment from the doctor, 'a request to
consent can be interpreted as guidance to consent.'
Harris [42] argues that at least where the costs and risks
involved are minimal, people will want to participate in
medical research. Overall, and in marked contrast to the
situation in previously reported trials that compared irre-
versible treatment strategies [19,20,32]) for often life-
threatening conditions [5,10,17-20], SANAD would seem
to represent a low-cost, low-risk trial making few demands
upon its participants beyond normal clinical care. How-
ever, the differentiation Harris makes between 'degree of
danger' and 'probability of occurrence of danger' is highly
relevant in the context of SANAD, since in relation to
treatment of epilepsy the degree of danger is small (side
effects of AEDs are generally of low severity whereas many
people fear experiencing further seizures), even though
the probability of occurrence is large (most people taking
AEDs report side-effects [49]). Thus, the conditions of
SANAD allowed the vast majority of patients approached
to agree to participation, but led a few for whom the prob-
ability of occurrence of danger was too high to decline.
Our study was limited by its small sample size, the failure
to interview all those initially agreeing to take part and the
fact that none of the parents who took part had declined
participation in SANAD. Informants were drawn from
only four of the 90 centres that took part in SANAD and
although we have no reason, based on analysis of the data
collected for the main trial, to suppose that our 23 'partic-
ipation study' informants were in any way different from
others recruited (or not) to SANAD, we cannot be certain
of this. The loss of 15 people from our original sample
may reflect the timing of the recruitment process, since
patients recruited to SANAD had just had a diagnosis of
epilepsy and the advisability of treatment confirmed. It
seems likely that for some, once they left the clinic and
had time to reflect on events, taking part in research
ceased to be a priority compared to the magnitude of thePage 11 of 13
(page number not for citation purposes)
Trials 2006, 7:32 http://www.trialsjournal.com/content/7/1/32clinical considerations presented. Like Corrigan [44], we
recognise that our informants may even have felt over-
whelmed by the research process and that willingness to
enrol in the participation study might have been
enhanced had we been able to separate study recruitment
from the clinical encounter. A further limitation previ-
ously highlighted was that we were unable to tape-record
the SANAD recruitment consultations, so that our account
of events rests solely on the recall and interpretations
given to them by informants.
Conclusion
Despite these limitations and the uncontroversial nature
of SANAD, our data suggest that further research is needed
to explore 'the myth and reality' [50] of trial recruitment
processes and informed consent; and of patient motiva-
tions, interpretations and misinterpretations. In particu-
lar, future examination of the concept of 'altruism'
demands a more nuanced approach; doctors' individual
approaches to information giving about trials and the
possibility of 'unwitting coercion' needs further consider-
ation; as does the possibility of therapeutic misconception
even in apparently straightforward trials. Our findings
have practical and ethical implications both for feedback
to recruiting clinicians in SANAD and for training of
future trial recruiters.
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